Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid

Bibliographic Details
Main Authors:	Taylor, P, Tarrant, J, Zhao, L, Gindin, Y, Mirza, A, Harrison, P, Tasset, C, Galien, R, Van der Aa, A, Downie, B
Format:	Conference item
Published:	BMJ Publishing Group 2018

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018)

Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials
by: Tarrant, J, et al.
Published: (2020)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
by: Taylor, P, et al.
Published: (2017)

Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
by: Jacqueline M. Tarrant, et al.
Published: (2020-01-01)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Filgotinib for the treatment of rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study
by: Westhovens, R, et al.
Published: (2016)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
by: Taylor, P, et al.
Published: (2020)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
by: Taylor, PC, et al.
Published: (2020)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
by: Taylor, P, et al.
Published: (2020)

Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2024)

Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
by: Tanaka, Y, et al.
Published: (2023)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-07-01)

Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis
by: Peter C. Taylor, et al.
Published: (2024-07-01)

Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-11-01)

Filgotinib-treated rheumatoid arthritis patients with high baseline neutrophil-to-lymphocyte ratio show better clinical response rates and patient-reported outcomes
by: Taylor, P, et al.
Published: (2021)

Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2021)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

JAK inhibitors in rheumatoid arthritis
by: Taylor, PC
Published: (2019)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Effect of filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials
by: Pope, J, et al.
Published: (2021)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
by: Taylor, P
Published: (2019)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

JAK Inhibitors in Rheumatoid Arthritis
by: Kathryn Biddle, et al.
Published: (2022-08-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
by: Mease, P, et al.
Published: (2018)

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
by: Jeffrey R. Curtis, et al.
Published: (2023-12-01)

JAK inhibitors for the treatment of rheumatoid arthritis
by: Akio Morinobu
Published: (2020-10-01)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
by: Taylor, PC, et al.
Published: (2023)

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
by: Toshimasa Shimizu, et al.
Published: (2023-03-01)

The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib
by: Yoshiya Tanaka, et al.
Published: (2024-11-01)

Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Taylor, PC, et al.
Published: (2024)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes
by: Zoltan Szekanecz, et al.
Published: (2025-03-01)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
by: Tanaka Y, et al.
Published: (2023-10-01)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
by: Orbai, A-M, et al.
Published: (2019)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotnib in adults with moderately-to-severely active rheumatoid arthritis with prior inadequate response to methotrexate (FINCH1)
by: Taylor, PC, et al.
Published: (2020)

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study
by: Arthur Kavanaugh, et al.
Published: (2025-01-01)

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid

Similar Items

Similar Items